BioMedical Enterprises announces patent for implant controller technology

BioMedical Enterprises has announced that the U.S. Patent Office awarded BME with the patent for "System and Method for Force, Displacement and Rate Control of Shape Memory Material Implants."

Covering 61 claims, patent number 7,240,677 provides protection for BME's innovative OSSforce Implant Controller technology rsIMProp.

The issued patent provides BME market exclusivity for years to come for the control of memory materials used in medicine. The patent covers instruments, methods and thus implants formed of shape memory material where the shape change is controlled. This patent covers any form of heat energy source such as, electrical resistive heating, conductive heating or inductive heating. This advanced technology for the use of shape memory materials, including nitinol, allows the surgeon for the first time to fully control a shape changing implant. rsIMProp.

BME's OSSforce Implant Controller is BME's first product utilizing the features described and claimed in the issued patent. These features give surgeons control over BME's extensive line of bone fusion devices such as the OSStaple and OSSplate. These devices, formed from nitinol, have a pre-programmed shape. When implanted in one configuration the OSSforce controls the extent of return of the implant to a second configuration. rsIMProp.

The musculoskeletal application of the OSSforce Implant Controller gives surgeons the ability to control the activation rate of the implant and the forces applied across the bone fusion interface. Implant forces can be decreased in osteoporosis cases to protect against iatrogenic fractures or can be increased in the healthy skeleton to provide maximum bone fixation. In the correction of deformities, the surgeon can change the shape of the implant to adjust for the growing adolescent. These variables are controlled while keeping the implant temperature below the point of thermal necrosis of tissue. rsIMProp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer extends agreement with genetic medicines customer